DailyWealth Investment Newsletter  

About DailyWealth Premium Content DailyWealth Archive
DailyWealth Investment Newsletter DailyWealth Contributors DailyWealth Resources DailyWealth Market Window
 
DailyWealth Print Edition Print Edition | Sponsored Link:
True Wealth Login

Warts
By Dan Ferris

December 21, 2006

“What gets me really excited about a guy is when he has warts, and everyone knows he has warts, and the warts just don’t matter.”

– Paul DePodesta, the then-assistant general manager of the Oakland Athletics major league baseball team.

DePodesta, who went on the serve as the Los Angeles Dodgers GM, wasn’t merely describing baseball. He was discussing the unique art of winning an unfair game...

“We don’t get the guys who are perfect,” DePodesta continued. “There has to be something wrong with them for them to get to us.”

Paul DePodesta’s fascination with “warts” began at Harvard. As an undergraduate there, DePodesta entered reams of data into a computer to find out what metrics in baseball correlated with winning. What numbers mattered, in other words. Most baseball fans would be surprised by what he discovered. Only two numbers really mattered for hitters: on-base percentage and slugging percentage. Both statistics give runners credit for earning walks, while the more popular batting average does not.

As you know, serious baseball fans revel in statistics. But, looking carefully at the numbers, DePodesta found everything else – all the stuff fans pay and overpay for – is meaningless. What turns out to be truly valuable in the game of baseball, the thing that really wins games, is simply avoiding outs. Getting walked or slapping grounders past the infielders. That’s how you win baseball games. No matter what anyone tells you, that’s what the numbers say.

Does this sound familiar? What the Oakland Athletics baseball team calls avoiding outs, we refer to as not losing money. For investors, that translates into one boring, slightly screwed up – but incredibly cheap – investment opportunity after another. Stocks with “warts.”

You’ll find plenty of “warts” in my newsletter’s portfolio: Companies that own lots of land that just sits there year after year; a stodgy utility company; an out-of-favor steel producer. I buy companies with cloudy near-term outlooks, companies that buy assets in the jungles of Africa, companies that can’t find anything better to do with cash than buy their own shares. That’s what you’ll find in the pages of Extreme Value, month after month.

There’s always something wrong with the stocks we buy, the same way the Oakland A’s baseball players seem too slow or too old or too awkward to win. But we’re not buying these “warts” for the novelty. We’re buying because it turns out that, despite the warts, these companies produce more wealth for investors than any other method of investing in common stocks.

In both businesses, the bureaucrats and experts are just as willfully ignorant. Several low-budget teams made the playoffs in the 2006 baseball season, and no megabudget teams made it to the World Series... the same way investors who lose money consistently buying expensive hyper-growth stocks don’t notice that the richest investors and most successful fund managers – Warren Buffett, Bill Nygren, Marty Whitman, Bill Ruane, Mario Gabelli – are all disciplined value investors.

I don’t buy stocks that are perfect. Perfect stocks are priced for perfection, like Google, which is currently priced as though it’s a sure thing to repeat this year’s record earnings performance – 118 more years in a row.

In Extreme Value, we buy the cheapest of the cheap, warts and all, knowing that the low price we’re paying is more important than any problems the company has. The fact that most people see the warts and don’t understand the importance of price gives us a decided edge over other investors.

Think about what’s popular in baseball, what really drives the fans wild. Footspeed, base stealing, home-run hitting… all of which Moneyball author Michael Lewis reveals to be highly overvalued by the market for major league baseball players.

Likewise, rapid earnings growth, stock splits, and hot new technologies all send most so-called investors into a buying frenzy. That’s what’s popular among investors, and it’s all dramatically overpriced.

So today’s advice is this: Put Moneyball by Michael Lewis on your Christmas list. Moneyball is the riveting story of how the Oakland Athletics baseball team wins so many games, even though it has the second lowest payroll in all of major league baseball. To order a copy of Moneyball, click here.

It’s a great read, but more importantly, you’ll never want to buy a stock again...

... unless it comes with warts.

Good investing,

Dan Ferris

Editor's note: Dan Ferris is a regular contributor to DailyWealth, a free investment newsletter focused on the world's best contrarian opportunities. We write with a simple belief in mind: You don't have to take big risks to make big money with your investments.

Sign up today to read more investment ideas from Dan Ferris.

Email a Friend

Delicious
Reddit

Digg

RSS

AND HERE WE GO AGAIN WITH THE RUSSIA FUND

The Templeton Russia Fund (TRF) is about to get crushed again.

Stuffed with Russian oil and bank stocks, this ETF is one of the few direct Russia plays in the market. It’s also one of our favorite gauges of optimism towards risky emerging markets like Brazil, Russia, and Indonesia. If investors are willing to pay a big premium to own the fund’s underlying assets, it indicates the market is in love with risk.

This spring, the premium on TRF hit a whopping 35%. You had to pay $1.35 for every $1 of real value. This huge overvaluation was corrected when emerging markets got obliterated in May. The Russia Fund fared the worst, falling 47% from its peak.

With emerging market speculation heating up again, TRF is trading for a 24% premium right now. If that premium climbs any higher, we predict another obliteration.

-Brian Hunt

Big Oil is keenly interested in northern Alberta's oil sands – a region of enormous oil deposits so thick they require extraordinary technology and expenditure to convert into fuel.

The majors, except BP, already are quite active there, lured by the opportunity for sizable returns. Suncor Energy is seen as a potential acquisition target, says Tom Ebbern, executive managing director of Calgary investment adviser Tristone Capital.

Suncor, with a $36.5 billion market cap, has very large oil-sands operations, plus refineries in Canada and the U.S. A smaller potential target, Mr. Ebbern says, is Nexen. The Calgary company has a $14 billion market cap.

-Wall Street Journal

Already, 7 of the world's top 20 container ports are in China, and their growth rates are outstripping the rest. Container traffic in Shanghai and seven other major Chinese ports grew an average 53 percent a year between 2003 and 2005, according to figures provided by Busan Port Authority.

-International Herald Tribune

China will unveil new rules this week aimed at restricting the number of foreigners who can adopt Chinese children, an official said on Wednesday, which foreign agencies say will ban the obese and unmarried from adopting.

China has become a popular destination in recent years for couples, especially Americans, wishing to adopt.

Girls account for the vast majority of adoptions because of a traditional Chinese preference for boys, and because China’s strict controls on family size results in many female babies being abandoned at birth.

-NewsMax

Home | About DailyWealth | Premium Content | DailyWealth Archive | Contributors
DailyWealth Resources | Research Reports | Privacy Policy

Customer Service: 1-888-261-2693 – Copyright 2010 Stansberry & Associates Investment Research. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This e-letter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Stansberry & Associates Investment Research, LLC. 1217 Saint Paul Street, Baltimore MD 21202